| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 10/14/2004 | WO2004087704A1 Azaindole derivatives, preparations thereof, uses thereof and compositions containing them |
| 10/14/2004 | WO2004087690A2 Benzimidazole derivatives and their use for modulating the gaba-a receptor complex |
| 10/14/2004 | WO2004087680A1 Novel quinazoline derivatives and methods of treatment related to the use thereof |
| 10/14/2004 | WO2004087669A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof |
| 10/14/2004 | WO2004087663A1 Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof |
| 10/14/2004 | WO2004087662A1 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors |
| 10/14/2004 | WO2004087658A1 Indolone-acetamide derivatives, processes for preparing them and their uses |
| 10/14/2004 | WO2004087646A2 Pyrrolidino-1,2-dicarboxy-1-(phenylamide)-2-(4-(3-oxo-morpholino-4-yl)-phenylamide) derivatives and related compounds for use as inhibitors of coagulation factor xa in the treatment of thrombo-embolic diseases |
| 10/14/2004 | WO2004087641A1 Hydrazone derivative |
| 10/14/2004 | WO2004087259A2 Pharmaceutical composition effective in treatment of mechanical allodynia, screening method of potential compound as said pharmaceutical composition, abd inspection method of mechanical allodynia |
| 10/14/2004 | WO2004087209A1 Preparation for sustaining therapeutically effective blood concentration of analgesic activity potentiator |
| 10/14/2004 | WO2004087195A2 Therapeutic use of modulators of notch and/or kruppel-like factors |
| 10/14/2004 | WO2004087168A1 Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders |
| 10/14/2004 | WO2004087166A1 Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| 10/14/2004 | WO2004087161A1 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders |
| 10/14/2004 | WO2004087160A1 Treatment of neurological conditions |
| 10/14/2004 | WO2004087156A1 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors |
| 10/14/2004 | WO2004087155A1 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors |
| 10/14/2004 | WO2004087137A1 Benzimidazole derivatives and their use for modulating the gabaa receptor complex |
| 10/14/2004 | WO2004087134A1 Use of the hydrochloride of the active ingredient base 1-[n2-[3,5-dibromo-n-[[4-(3,4-dihydro-2(1h)-oxoquinazolin-3-yl)-1-piperidinyl]-carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)-piperazine combined with sumatriptan for the treatment of migraines |
| 10/14/2004 | WO2004087125A1 Amino acid derivatives as inhibitors of mammalian sodium channels |
| 10/14/2004 | WO2004087124A1 Compounds having serotonin 5-ht17 receptor antagonist activity and muscarinic m4 receptor agonist activity and their use in the treatment of psychotic disorders |
| 10/14/2004 | WO2004087116A2 Drug combination for motor dysfunction in parkinson's disease |
| 10/14/2004 | WO2004087073A2 Treatment of demyelinating conditions |
| 10/14/2004 | WO2004073583A3 Use of antimuscarinic drugs for preventing the onset of epilepsy |
| 10/14/2004 | WO2004071416A3 Novel inhibitors of formation of advanced glycation endproducts (ages) |
| 10/14/2004 | WO2004071392A8 Diagnostics and therapeutics for diseases associated with acetylcholine receptor, muscarinic 4(m4) |
| 10/14/2004 | WO2004071152A3 Use of s-10 hydroxy-10, 11-dihydro-carbamazepine for the treatment of anxiety and bipolar disorders |
| 10/14/2004 | WO2004067550A3 Novel use of mifepristone and derivatives thereof as hedgehog protein signalling pathway modulators and applications of same |
| 10/14/2004 | WO2004042402A3 Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1) |
| 10/14/2004 | WO2004042076A3 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4a (pde4a) |
| 10/14/2004 | WO2004041245B1 Pharmaceutical solutions comprising a modafinil compound and their use for the manufacture of a medicament for treating different diseases |
| 10/14/2004 | WO2004016769A3 Antibodies directed to monocyte chemo-attractant protein-1 (mcp-1) and uses thereof |
| 10/14/2004 | WO2004005256A3 Substituted 4-phenyl-piperidin-amides as tachykinin antagonists and serotonin reptake inhibitors |
| 10/14/2004 | WO2004000785A3 Phenyloxyalkanonic acid derivatives as hppar activators |
| 10/14/2004 | WO2004000781A3 Nitrooxyderivatives of cyclooxygenase-2 inhibitors |
| 10/14/2004 | WO2004000762A3 Propionic acid derivatives and their use as hppars activators |
| 10/14/2004 | WO2003104811A3 Diagnostic and therapeutic use of steroidogenic acute regulatory protein for neurodegenerative diseases |
| 10/14/2004 | WO2003104282A3 Glycoprotein vi - fc fusion protein for treating vascular disorders |
| 10/14/2004 | WO2003100092A3 Diagnostic and therapeutic use of cyp11a1 for neurodegenerative diseases |
| 10/14/2004 | WO2003007936A8 Carbamate compounds for use in preventing or treating neuropathic pain and cluster and migraine headache-associated pain |
| 10/14/2004 | WO2002030980A8 Use of anti-human integrin alpha d antibodies to treat spinal cord injury |
| 10/14/2004 | US20040204673 Modular infusion device and method |
| 10/14/2004 | US20040204596 preventing or treating degradation of collagen, degradation of collagen by bacterial collagenases during a bacterial infection, regeneration of skin and ligaments, tumoral invasion and degenerative diseases having fibrinoid degeneration of collagen |
| 10/14/2004 | US20040204584 Alzheimer's disease; Parkinson's disease; antidepressants |
| 10/14/2004 | US20040204582 Substituted sulfonamides and ureas useful for inhibiting kinase activity |
| 10/14/2004 | US20040204564 CRFR1 selective ligands |
| 10/14/2004 | US20040204500 Preventives/remedies for organ functional disorders and organ dysfunction |
| 10/14/2004 | US20040204495 Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment of prevention of pain and/or headache disorders |
| 10/14/2004 | US20040204482 provides a defined blood concentration profile having no rapid initial rise in blood plasma concentration of the good soluble active substance when administered; (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide; nervous system, gastrointestinal, heart disorders, Alzheimer's |
| 10/14/2004 | US20040204477 For use as antiproliferative agents |
| 10/14/2004 | US20040204476 Oxopyrrolidine compounds, preparations of said compounds and their use in the manufacturing of levetiracetam and analogues |
| 10/14/2004 | US20040204469 Use of cox-2 inhibitors for the treatment of schizophrenia, delusional disorders, affective disorders, autism or tic disorders |
| 10/14/2004 | US20040204467 Use of 5HT3-receptor-antagonists |
| 10/14/2004 | US20040204465 Crystal form of N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide |
| 10/14/2004 | US20040204464 Isoxazoline compounds having MIF antagonist activity |
| 10/14/2004 | US20040204460 Sodium channel modulators |
| 10/14/2004 | US20040204457 Use of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4- piperidinemethanol or its prodrug in the treatment of symptoms of dementia and dopamine induced psychosis |
| 10/14/2004 | US20040204456 Methods for treatment of cognitive and menopausal disorders with D-threo methylphenidate |
| 10/14/2004 | US20040204453 For therapy of irritable bowel syndrome, drug addiction or dependency, including alcohol addiction, depression, anxiety, schizophrenia, anxiety, schizophrenia and eating disorders |
| 10/14/2004 | US20040204452 to decompose peroxynitrite anion into harmless nitrate or nitrite endproducts which prevents the free radical-mediated cell damage; cytoprotective; Alzheimer's disease; 3,5-dimethylisoxazole-4-sulfonic acid 4-pyrrolidin-1-ylphenylamide |
| 10/14/2004 | US20040204449 New isoquinoline compounds |
| 10/14/2004 | US20040204445 2-Azabicyclo[3.3.1]nonane derivatives |
| 10/14/2004 | US20040204437 Substituted arylamine derivatives and methods of use |
| 10/14/2004 | US20040204428 Derivatives of triazolyl-imidazopyridine and of the triazolylpurines useful as ligandsof the adenosine a2a receptor and their use as medicaments |
| 10/14/2004 | US20040204422 N-[(Piperazinyl)hetaryl]arylsulfonamide compounds |
| 10/14/2004 | US20040204416 Pharmaceutical composition for the treatment of CNS and other disorders |
| 10/14/2004 | US20040204415 Pyrrolo[1,2-B]pyridazine compounds and their uses |
| 10/14/2004 | US20040204414 Pyrrolo[1,2-B]pyridazine compounds and their uses |
| 10/14/2004 | US20040204413 Pharmaceutical compositions containing a COX-II inhibitor and a muscle relaxant |
| 10/14/2004 | US20040204411 Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of reboxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| 10/14/2004 | US20040204409 Useful as antagonists of NMDA (N-methyl-D-aspartate) NR2B receptor; for therapy of pain, stroke, traumatic brain injury, Parkinson's disease, Alzheimer's disease, depression, anxiety, migraine |
| 10/14/2004 | US20040204403 Pharmaceutical composition comprising ibuprofen and prochlorperazine |
| 10/14/2004 | US20040204387 administering to subject a pharmaceutically effective amount of inositol stereoisomers, enantiomers or derivatives thereof; for treating or preventing condition of central or peripheral nervous system or systemic organ associated with a disorder in protein folding or aggregation, or amyloid formation |
| 10/14/2004 | US20040204368 Oxadiazole derivative compounds and drugs containing these compounds as the active ingredient |
| 10/14/2004 | US20040204364 Peptides for activation and inhibition of deltaPKC |
| 10/14/2004 | US20040204347 administering an effective amount of an inhibitor of the interaction of glutamate with the alpha -amino-3-hydroxy-5-methyl-4-isoxazole-propionate (AMPA) receptor complex to treat demyelinating disorders |
| 10/14/2004 | US20040204345 Using recombinant zinc finger proteins; use in human therapeutic applications such as cancer therapy and altering plant phenotypes, including disease resistance, fruit ripening |
| 10/14/2004 | US20040204344 bifunctional molecules containing at least one metal-chelating group associated with at least one amyloid-binding group e.g a benzothiazole derivative; for treating pathophysiological condition selected from Alzheimer's disease, Down's syndrome, Lewy body dementia, Guam Parkinson-Dementia, head trauma |
| 10/14/2004 | US20040204341 Nr2b receptor antagonists for the treatment or prevention of migraines |
| 10/14/2004 | US20040203128 Use of PP2A phosphatase modulators in the treatment of mental disorders |
| 10/14/2004 | US20040203118 Polynucleotides and polypeptides of the IFNalpha-14 gene |
| 10/14/2004 | US20040203104 for drug screening enzyme inhibitors; genetic engineering; comprising subjecting the sample to a polymerase chain reaction, a northern hybridization assay or an in situ hybridization assay |
| 10/14/2004 | US20040203099 Conjugate of a transport protein and a protein for modulation of notch signalling |
| 10/14/2004 | US20040203097 Kinases and phosphatases |
| 10/14/2004 | US20040203045 Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases |
| 10/14/2004 | US20040203014 Neurotransmisson-associated proteins |
| 10/14/2004 | US20040202736 Method of ameliorating side-effects of SERMs |
| 10/14/2004 | US20040202707 self-adhesive matrix based on polysiloxanes and containing capsaicin contains liquid microreservoir droplets of an amphiphilic solvent, in which the capsaicin is dissolved |
| 10/14/2004 | US20040202656 Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders |
| 10/14/2004 | US20040202651 Uses of anti-insulin-like growth factor 1 receptor antibodies |
| 10/14/2004 | US20040202617 Delivery of opioids through an inhalation route |
| 10/14/2004 | DE10315573A1 Substituierte Pyrazole Substituted pyrazoles |
| 10/14/2004 | DE10315572A1 Substituierte Pyrazole Substituted pyrazoles |
| 10/14/2004 | DE10315571A1 Pyrazolverbindungen Pyrazole |
| 10/14/2004 | DE10314617A1 Verwendung des Hydrochlorids der Wirkstoffbase Use of the hydrochloride of the active substance base 1-[N2-[3,5-Dibrom-N-[[4-(3,4-dihydro-2(1H)-oxochinazolin-3-yl)-1-piperidinyl]-carbonyl]-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)-piperazin in Kombination mit Sumatriptan zur Behandlung von Migräne in combination with sumatriptan for migraine |
| 10/14/2004 | CA2521371A1 Use of carbamazepine derivatives for the treatment of agitation in dementia patients |
| 10/14/2004 | CA2521274A1 Combinations comprising anti-epileptic drugs for the treatment of neurological disorders |
| 10/14/2004 | CA2521191A1 Pyrrolo (1,2-b) pyridazine compounds and their use as cfr-1 receptor antagonists |
| 10/14/2004 | CA2521172A1 4-(2-phenylsulfanyl-phenyl)-1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors |